LT3335709T - Gama-hidroksibutirato kompozicijos ir jų naudojimas sutrikimams gydyti - Google Patents

Gama-hidroksibutirato kompozicijos ir jų naudojimas sutrikimams gydyti

Info

Publication number
LT3335709T
LT3335709T LTEP17202548.8T LT17202548T LT3335709T LT 3335709 T LT3335709 T LT 3335709T LT 17202548 T LT17202548 T LT 17202548T LT 3335709 T LT3335709 T LT 3335709T
Authority
LT
Lithuania
Prior art keywords
disorders
gamma
treatment
hydroxybutyrate compositions
hydroxybutyrate
Prior art date
Application number
LTEP17202548.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Clark P. Allphin
Michael Desjardin
Original Assignee
Jazz Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3335709(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Limited filed Critical Jazz Pharmaceuticals Ireland Limited
Publication of LT3335709T publication Critical patent/LT3335709T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LTEP17202548.8T 2012-12-14 2013-12-13 Gama-hidroksibutirato kompozicijos ir jų naudojimas sutrikimams gydyti LT3335709T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737695P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
LT3335709T true LT3335709T (lt) 2020-11-25

Family

ID=49596603

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17202548.8T LT3335709T (lt) 2012-12-14 2013-12-13 Gama-hidroksibutirato kompozicijos ir jų naudojimas sutrikimams gydyti

Country Status (24)

Country Link
US (10) US8591922B1 (enExample)
EP (3) EP3335709B1 (enExample)
JP (1) JP6215347B2 (enExample)
KR (1) KR102180343B1 (enExample)
CN (1) CN105025892B (enExample)
AU (1) AU2013359114B2 (enExample)
CA (1) CA2894876C (enExample)
CY (2) CY1119918T1 (enExample)
DK (2) DK3335709T3 (enExample)
ES (2) ES2660056T3 (enExample)
HR (1) HRP20201685T1 (enExample)
HU (1) HUE051060T2 (enExample)
IL (1) IL239355A (enExample)
IN (1) IN342829B (enExample)
LT (1) LT3335709T (enExample)
MX (1) MX366681B (enExample)
NO (1) NO3027826T3 (enExample)
PL (1) PL2931268T3 (enExample)
PT (2) PT2931268T (enExample)
SG (1) SG11201504637TA (enExample)
SI (1) SI3335709T1 (enExample)
TR (1) TR201802271T4 (enExample)
TW (2) TWI639425B (enExample)
WO (1) WO2014093791A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) * 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程(武汉)有限公司 γ-羟基丁酸的前药及其组合物和用途
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
US12514818B2 (en) 2017-12-18 2026-01-06 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
KR20220119429A (ko) * 2019-12-24 2022-08-29 재즈 파마슈티칼즈 아일랜드 리미티드 감마-히드록시부티레이트(ghb) 투약
TW202139986A (zh) * 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR102436227B1 (ko) * 2020-05-29 2022-08-24 주식회사 케이티앤지 기능성 물질이 코팅된 흡연물품용 팁페이퍼 및 상기 팁페이퍼의 코팅 방법
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
AU2021362222A1 (en) 2020-10-16 2023-06-01 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
US20240182401A1 (en) * 2021-03-20 2024-06-06 Alkem Laboratories Limited A process for the preparation of mixed oxybate salts and polymorphs thereof
US11877992B1 (en) 2021-06-07 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of learning disorders
US11877993B1 (en) 2021-06-23 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of psychological disorders
EP4415701A1 (en) 2021-10-11 2024-08-21 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP2025513295A (ja) * 2022-04-21 2025-04-24 ゼブラ セラピューティクス, インコーポレイテッド ガンマ-ヒドロキシブチラート送達化合物ならびにその作製および使用のためのプロセス
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US4374441A (en) 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
IT1283782B1 (it) 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
US6495598B1 (en) 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
FR2817256B1 (fr) 2000-11-27 2005-07-15 Univ Pasteur Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8410304B2 (en) 2009-04-15 2013-04-02 Norac Pharma Process for preparing gamma-hydroxybutyrate
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
ES2827005T3 (es) 2021-05-19
US20220000815A1 (en) 2022-01-06
US20170209396A1 (en) 2017-07-27
EP3335709B1 (en) 2020-08-12
ES2660056T3 (es) 2018-03-20
TWI681770B (zh) 2020-01-11
MX2015007531A (es) 2016-03-11
KR102180343B1 (ko) 2020-11-19
EP2931268A4 (en) 2016-06-01
TW201429469A (zh) 2014-08-01
US20190224149A1 (en) 2019-07-25
US20240156759A1 (en) 2024-05-16
WO2014093791A1 (en) 2014-06-19
US8901173B2 (en) 2014-12-02
CN105025892A (zh) 2015-11-04
DK3335709T3 (da) 2020-10-19
SG11201504637TA (en) 2015-07-30
IL239355A (en) 2017-05-29
US11554102B2 (en) 2023-01-17
HUE051060T2 (hu) 2021-03-01
EP3799867A1 (en) 2021-04-07
US10195168B2 (en) 2019-02-05
AU2013359114B2 (en) 2017-01-19
CA2894876A1 (en) 2014-06-19
PL2931268T3 (pl) 2018-06-29
US20140171505A1 (en) 2014-06-19
EP2931268A1 (en) 2015-10-21
CY1123498T1 (el) 2022-03-24
US20260183254A1 (en) 2026-07-02
IN342829B (enExample) 2016-07-01
US20160058720A1 (en) 2016-03-03
CA2894876C (en) 2017-08-29
KR20150100737A (ko) 2015-09-02
JP2016503762A (ja) 2016-02-08
EP2931268B1 (en) 2017-11-22
TW201831174A (zh) 2018-09-01
CY1119918T1 (el) 2018-06-27
US10675258B2 (en) 2020-06-09
NO3027826T3 (enExample) 2017-12-16
MX366681B (es) 2019-07-19
EP3335709A1 (en) 2018-06-20
US9132107B2 (en) 2015-09-15
IL239355A0 (en) 2015-07-30
TR201802271T4 (tr) 2018-03-21
BR112015014007A2 (pt) 2017-07-11
US9555017B2 (en) 2017-01-31
SI3335709T1 (sl) 2021-01-29
US20200338029A1 (en) 2020-10-29
AU2013359114A1 (en) 2015-07-02
US8591922B1 (en) 2013-11-26
DK2931268T3 (en) 2018-02-26
TWI639425B (zh) 2018-11-01
PT2931268T (pt) 2018-02-27
PT3335709T (pt) 2020-10-21
CN105025892B (zh) 2018-03-20
US20140171506A1 (en) 2014-06-19
JP6215347B2 (ja) 2017-10-18
HK1215181A1 (en) 2016-08-19
HRP20201685T1 (hr) 2020-12-25

Similar Documents

Publication Publication Date Title
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
IL256624B (en) Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
IL225239A0 (en) Compounds for the treatment of acne and related diseases
EP2552433A4 (en) COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
HUE039687T2 (hu) Kompozíciók, amelyek alkalmazhatók KIT-tel kapcsolatos rendellenességek kezelésében való alkalmazásra
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
SG10202013014RA (en) Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
ZA201408055B (en) Compositions and methods for the treatment of local pain
PL2838539T3 (pl) Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych
ZA201408056B (en) Compositions and methods for the treatment of mucositis
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
IL234616A0 (en) A herbal preparation for the treatment of metabolic diseases
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
ZA201408045B (en) Compositions and methods for the treatment of inflammation and lipid disorders
GB201303721D0 (en) Compositions for treatment of sleep disorders